Immune Checkpoint Inhibitors Related Diabetes Mellitus:
A Report of 2 Cases and Literature Review.
10.3779/j.issn.1009-3419.2021.102.54
- Author:
Yaoyao REN
1
;
Linlin ZHANG
1
;
Yu WANG
2
;
Diansheng ZHONG
1
Author Information
1. Department of Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
2. Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Review
- Keywords:
Diabetes mellitus;
Immune checkpoint inhibitor;
Lung neoplasms
- MeSH:
Aged;
Blood Glucose;
Diabetes Mellitus/drug therapy*;
Female;
Humans;
Immune Checkpoint Inhibitors/adverse effects*;
Lung Neoplasms/drug therapy*
- From:
Chinese Journal of Lung Cancer
2022;25(1):61-65
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) are widely used in clinic, and the incidence of rare adverse events are increasing. The aim of this paper is to better define the rare adverse effect of diabetes mellitus associated with ICIs. We report 2 cases of diabetes mellitus associated with ICIs. Literature review was conducted and we discussed the clinical presentation, potential mechanisms and suggestions for optimal management. Two patients were both elderly women, case 1 had increased blood glucose after 7 months of using Durvalumab, and cases 2 had diabetic ketoacidosis after 6 weeks of using Pembrolizumab. Both patients were administered exogenous insulin to control blood glucose. Case 1 has been treated with Durvalumab until now and case 2 discontinued using of Pembrolizumab. HLA genotypes and other factors may explain the risk factors of diabetes associated with ICIs in some individuals. Diabetes mellitus associated with ICIs is an uncommon but potentially life-threatening endocrine system adverse event, which requires doctors to be vigilant. The patients who use ICIs need to monitor blood glucose. If they have hyperglycemia, endocrinologists should be asked to assist in diagnosis and treatment.
.
